Restless Legs Syndrome (RLS) is a well-de®ned symptom complex and is frequently associated with sleep disturbance and a recognized family history. It occurs either as idiopathic RLS or in association with many medical, neurological or vascular disorders. The neurological examination and routine investigations in idiopathic RLS are normal. Polysomnography supports the diagnosis of RLS by documenting the associated sleep disturbances and periodic limb movements in sleep (PLMS). Although MRI studies disclose no intracerebral lesions, recent Positron Emission Tomography (PET) and single photon emission computed tomography (SPECT) studies point to some involvement of the basal and red nuclei and the cerebellum. No de®nitive etiology is known for this condition, but several pathophysiological mechanisms have been proposed. There is supportive evidence that RLS is a Central Nervous System (CNS) dysfunction, suggesting widespread involvement of the descending dopaminergic (DA) pathways, possibly originating in the diencephalon or upper brainstem. This is corroborated by the successful treatment of RLS with DA agents, sedatives, and neurotransmitters. However, RLS can also occur with spinal disorders and spinal cord lesions implying the existence of a spinal generator. The incidence of RLS in pregnancy is well known and its association with vascular disorders supports another mechanism in some patients. The primary treatment of RLS is largely symptomatic and quite eective with DA agents, DA agonists, opioids and other neurotransmitters. The treatment of RLS associated with various diseases is aimed at the correction of the underlying pathological or de®ciency states. Antidepressant medications frequently precipitate or worsen the condition of RLS. Spinal Cord (2001) 39, 125 ± 133
Frequency and onset
The syndrome of restless legs (RLS) was probably ®rst described by Thomas Willis in 1672. 1 Ekbom, however, described the condition extensively and named it restless legs syndrome'. 2 Therefore, it is sometimes referred to as`Ekbom syndrome'. 3 RLS occurs either as idiopathic or in association with many medical conditions. It is not uncommon, aicting 1% to 15% of the population and is equally distributed between men and women. 4, 5 It is, however, more prevalent in older people and in them aects women about twice as often as men and also manifests more severe symptoms. 6, 7 RLS is the fourth leading cause of insomnia and is diagnosed in 10% to 20% of patients suering from that condition. 8 RLS may be static, but typically has a chronic and progressive course. Occasionally, remissions may occur in which the symptoms decrease signi®cantly or cease for a period of time but more often symptoms remain and worsen. 4, 9, 10 The incidence of RLS in pregnancy, usually in the second half of gestation, can be as high as 11% to 27%. 5, 11, 12 The symptoms often appear initially during pregnancy and after delivery may disappear for many years. 1, 4 The onset of idiopathic RLS begins at any age, even in infancy and early childhood. 13, 14 In a study by Walters et al, 9 a third of the patients experienced their ®rst symptoms before the age of 20. Frequent misdiagnoses in children and young adults arè growing pains', attention de®cit and hyperactivity disorders. 13, 15 Although RLS aects millions of people, it is rarely diagnosed by clinicians and most healthcare providers do not know of its existence. 16, 17 Some suggest that Caucasians and Asians are at higher risk, although little data about racial prevalence are available.
Diagnostic features
The diagnosis of RLS remains a clinical one based on subjective complaints. Therefore, the international RLS Study Group 14 developed and de®ned as minimal criteria for diagnosis of RLS the following four features.
Paresthesias
These abnormal sensations are variably described as tingling, burning, crawling, aching, grabbing or painful and are commonly associated with an urge to move. Some patients report an urge or inner feeling of restlessness without any clear precipitating sensations, while others report an indescribable uncomfortable feeling in their extremities or merely a need to move the limbs. 11, 14, 19 The paresthesias aect primarily the legs, especially the calves, and may be bilateral or unilateral. About 20% to 30% of patients experience similar sensations in the arms but rarely in the trunk or elsewhere in the body. 4 
Motor restlessness
This is de®ned as any activity that can relieve the urge to move. Patients typically walk around or pace thē oor. A wide variety of movements may be tried for relief such as rocking, stretching and¯exing the legs, jiggling while seated, deep knee bends, riding an exercise bicycle or tossing and turning in bed. Some patients describe bene®ts simply by standing. These varied movements are under voluntary control and although they can be suppressed by the patients, this may then greatly increase their discomfort. As an alternative, some patients resort to rubbing the leg or foot or taking hot or cold baths as a counter-stimulus to the leg sensations. 4, 14, 20, 21 3. Worsening of symptoms with relaxation A distinctive and unusual characteristic of RLS is that the sensory and motor symptoms are evoked by rest, either during quiet wakefulness or on attempts to sleep. Symptoms are worse when lying down or sitting with at least partial and temporary relief by activity. 4, 14, 18 4. Variability of symptoms Over the course of the day/night cycle, symptoms are worse in the evening and early in the night. Patients are less bothered during the daytime and often obtain some relief near dawn.
Associated features

Sleep disturbance
Patients primarily have diculty getting to sleep and staying asleep. Their periodic limb movements in sleep (PLMS) can arouse and awaken them. 3 In severe cases patients obtain only a few hours of sleep at night followed by excessive daytime sleepiness. PLMS and sensory symptoms in RLS are in¯uenced by a circadian rhythm that may be contributing to nighttime worsening. 22 
PLMS
These are repetitive, often stereotyped movements that typically recur at intervals of 15 to 40 s during non-REM sleep. They usually involve the legs, but may sometimes involve the arms. Involuntary limb movements may also occur while awake and at rest. Synonyms for these include resting`dyskinesias while awake' (DWA). Between 70% to 90% of patients with RLS will have PLMS on polysomnographic studies and approximately 1/3 of those with PLMS will have RLS as well.
1 PLMS are sometimes absent in patients with idiopathic RLS and similarly PLMS may occur independently of RLS. 4, 14 3. Dyskinesia This occurs while awake and almost exclusively at rest. These are typically brisk movements commonly occurring in the legs; they may occur at random, periodically, or in clusters. They may take variable forms but most characteristically they are¯exion jerks.
14 According to Kuny, 23 RLS patients display à depressive-anxiety, hypochondric expression'.
Family history
Although idiopathic RLS can occur sporadically, a family history suggestive of autosomal dominant inheritance is found in 25% to 60% of patients. 9, 14, 17 In contrast, only 13% of the secondary RLS patients have a positive family history. 18, 24 Genetic studies are currently underway. Using DNA mapping techniques, preliminary linkage studies reported a possible candidate gene locus for RLS. 1 Trenkwalder et al 10 described a studied kindred of familial RLS with 20 aected members investigated in four generations. All patients showed sensory symptoms of their legs and worsening of symptoms with increasing age. The mean age of onset fell from 51.5 years in the second generation to 19.8 years in the fourth generation. Winkelmann et al 25 analysed 300 patients from 16 families and found 42.3% of patients with idiopathic and 11.7% with uremic RLS as de®nite hereditary RLS. They also found that patients with familial RLS had their onset of symptoms at a younger age and signi®cant worsening of symptoms during pregnancy. Walters et al 26 studied a mother and her three children, as well as a 26-year-old patient from a second family, with typical signs of RLS and emphasized the occurrence in childhood and adolescence. One of the largest studies aected 81 family members and showed a preponderance of females (1.4 : 1) and variations in penetrance and anticipation, which suggested possible genetic heterogeneity. 27 Other studies of aected family members with RLS, some of them spanning three to ®ve generations, have been reported. 28, 29 Potential underlying causes RLS is found to be associated with a wide variety of conditions which include medical, neurological, vascular disorders and also exogenous substances. The high incidence of RLS in the second half of pregnancy has already been pointed out. Although the majority of suggested causes are from anecdotal reports, several medical conditions have been well studied.
Among the medical disorders and the metabolic abnormalities are Mg, Fe, Folate, Vitamin A and Vitamin B de®ciencies, blood dyscrasias and all anemias. Machtey 30 raised the question of regarding RLS as a metabolic abnormality of primary or secondary type, mostly aecting the elderly.
Twenty-®ve per cent of patients with iron de®ciency anemia have symptoms of RLS. 31 Abnormally low serum iron (62.5%) and iron saturation (77%) levels were demonstrated in a relatively large population of patients with RLS. These measurements may re¯ect an as yet unidenti®ed defect of iron transport or metabolism. 32 Whether the iron de®ciency is primarily responsible for causing RLS or whether it simply aggravates the symptoms has not been determined. 17 RLS patients are also found to have fewer symptoms if their ferritin levels are greater than 50 mcg/l. 35 Iron de®ciency may impair the normal production of dopamine by interfering with the function of an iron containing protein in D2 receptors.
The high frequency (15% to 40%) of RLS in patients with uremia and renal failure on dialysis is well known. 8, 14 The prevalence in patients with endstage renal disease is equally high (20% to 40%). 34 After successful kidney transplantation, RLS can resolve.
1 Collado-Seidel et al, 35 in a study of uremic patients with RLS found signi®cantly lower intact parathyroid hormone level secretions.
Symptoms of RLS were signi®cantly prevalent in patients with ®bromyalgia (31%) and in rheumatoid arthritis (15%). 36, 37 Other medical conditions in which symptoms of RLS are observed are diabetes, chronic respiratory insuciency, post-gastrectomy states, Sjoegren's syndrome, hypothyroidism, porphyria and carcinoma among many others. 1, 11, 38 Familial amyloidosis resulting in peripheral neuropathy has also been thought to be associated. 39 Neurological disorders in which RLS is frequently observed include chronic myelopathy; diabetic, alcoholic, and chronic idiopathic polyneuropathy; Parkinson's disease and REM behavior disorders. 5, 11 In a group of patients evaluated for polyneuropathy, 5% had symptoms of RLS. These patients had mild predominantly sensory polyneuropathy. 40 RLS seems not uncommon in cryoglobulinemic neuropathy where it is signi®cantly associated with symmetrical sensory polyneuropathy. 41 A patient with polyneuropathy secondary to Lyme disease developed RLS; the latter symptoms improved after treatment with antibiotics alone. 40 A more unusual case of RLS triggered by lumbosacral radiculopathy was reported by Walters et al. 42 Lee et al 43 discussed sleep-related PLM associated with spinal cord lesions. Glasauer and Egnatchik 44 reported a patient presenting with symptoms of RLS and considered the presence of a foramen magnum meningioma as its etiology. Hemmer et al 45 reported the onset of RLS following thoracic myelitis due to neuro-borreliosis. In this case the symptoms of RLS developed during the period of recovery. Another reported possible etiology for RLS is saphenous nerve compression. 46 Gemignani et al 47 found an unexpectedly high incidence of RLS (37%) in patients with Charcot-Marie-Tooth disease, type 2. RLS was also found in 45% of patients with spinocerebellar ataxia, type 3 (CSC 3), but rarely in patients with genetically dierent types of autosomal dominant cerebellar ataxia. 48 In a recent study by Oboler et al, 49 peripheral vascular disease, hypocalcemia and coronary artery disease were all found to have signi®cantly increased odds ratios in patients with RLS. Other vascular disorders included venous insuciency and peripheral micro-embolism. 50 A higher incidence of RLS was also found in patients with both saphenous and nontruncal varicose vein disease. 51 In a study of cardiac patients, 6% reported moderate to severe RLS symptomatology. 52 Although the adverse eect of caeine and alcohol on RLS is well known, medications such as lithium, neuroleptics and others have a similar eect. An extensive list of conditions associated with RLS-PLMS is reported by O'Keee 11 and others. 19, 53 Neurological and laboratory ®ndings
The neurological examination in patients with idiopathic RLS is usually normal. 4, 19 Electromyogram (EMG) and nerve conduction studies may document any accompanying peripheral neuropathy or radiculopathy. 10, 14 Electrophysiological testing in primary RLS patients suggests that polyneuropathy is of an axonal nature. 40 Based on morphometric analysis of sural nerves which showed a signi®cant reduction in myelinated ®ber density, Iannacone et al 54 suggested that axonal neuropathy is often present in patients with primary RLS. Trenkwalder et al 55 observed that electromyographically measured muscle contractions were preceded by sensory discomfort in all patients with RLS. No dierence in the recorded patterns was observed between patients with idiopathic and uremic RLS. EMG and recruitment pattern and the probable persistence during sleep as PLMS supported their hypothesis of a propriospinal origin of these involuntary jerks. Doppler sonography of the legs should be performed to identify possible underlying disorders. Polysomnography, especially all night studies, supports the diagnosis of RLS by documenting the sleep disturbances and PLMS by the K complex. The K complex is the characteristic wave of stage II sleep and occurs with the leg jerk in PLMS, roughly assuming the time course of cyclical, alternating pattern. 11, 53, 56 The relationship of RLS and the occurrences of K complexes and alpha activity have been described. 57 There is also an important positive correlation between PLM and K complexes in spinal cord injured and non-paraplegic subjects. 58 All night polysomnographic ®ndings showed that increasing sleep latency, number of awakenings and decreasing sleep eciency all were associated with worsening of symptoms. 17, 59 Sleep quality was estimated to be worse in uremic RLS, suggesting that uremia itself worsens the motor symptoms of RLS, probably as a result of increased excitability. 60 Trenkwalder et al 22 found the circadian rhythm of the RLS of particular interest because DA drugs play a major role in its treatment. Because human studies also show evidence for circadian variation in DA and related noradrenergic neurotransmission, it is possible that the circadian factor in RLS is related to changes in catecholamine activity. It is further intriguing that circadian variations in the activity of these neurotransmitters in¯uence melatonin synthesis, which may be important for sleep regulation. Based on the striking response of RLS patients to DA agents and the suggestion that DA plays a key role in the pathogenesis of this condition, these authors 61 concluded that this response suggests that any DA de®cit is likely to be presynaptic, but possiblỳ upstream' from dopa-decarboxylase. They have not investigated postsynaptic receptors in RLS.
Latency of the soleus H re¯ex and the duration and onset latency of the direct and indirect blink re¯ex responses studied in idiopathic RLS patients were all normal. MRI studies showed no structural lesions in patients with idiopathic RLS. 62 However, in patients with Multiple Sclerosis (MS) who also suered from RLS, higher MRI lesion loads were found in infratentorial regions compared to patients without RLS. 63 Similarly, electron microscopy showed no structural abnormalities in peripheral nerve endings. 64 Adler et al 65 found olfactory function to be normal in patients with idiopathic RLS but signi®cantly reduced in patients with Parkinson's disease. Prolactin and cortisol plasma levels were normal in RLS patients that were never medicated suggesting a normal circadian rhythm. 66 Somatosensory and brainstem auditory evoked responses were normal. Tergau et al 67 demonstrated signi®cantly reduced intracortical inhibition for both foot and hand muscles by paired transcranial magnetic stimulation, suggesting that the entire motor cortex is disinhibited in RLS.
SPECT studies support the association between pain and decreased regional cerebral blood¯ow (rCBF) to the caudate nucleus as reported in ®bromyalgia syndrome. The increase in anterior cingulate rCBF with increasing pain also corroborates the ®ndings of increased thalamic rCBF during pain stimulation. 68 Recent functional MRI and PET scanning have drawn attention to the possible role of upper brainstem, diencephalon, red nucleus and cerebellum in the pathogenesis of RLS. Patients with RLS show normal 18 F-dopa striatal (putamen) uptake, but D2 binding is mildly (10%) reduced in the putamen and caudate nucleus. 1, 3, 17, 61, 67, 69 A SPECT study with I-123 IBZM, a speci®c D2-receptor ligand, showed a decrease in D2-receptor binding sites in the striatum of patients with RLS. 70, 71 Bucher et al,
72
using high-resolution functional MRI, localized cerebral generators associated with sensory leg discomfort (SLD) in RLS. Patients with SLD showed signi®cant activation in the cerebellum bilaterally and in the contralateral thalamus. The combined SLD/PLMS condition was associated with bilateral cerebellar and red nucleus activation.
Possible etiologies
The exact cause of RLS is not known but the condition is characterized by no known abnormality of either muscle or peripheral nerves. 5 However, there is supportive evidence that RLS is a CNS dysfunction and probably more than one mechanism is implicated.
RLS is considered a disorder of the central sensorymotor integration and the pathophysiological mechanism suggests an imbalance between the serotogenic and dopaminergic pathways involving the descending dopaminergic system. 24, 53, 73 However, the occurrence of RLS and PLMS in numerous conditions indicates that more than one neurotransmitter and pathway may be involved. The popular hypothesis has been that the dopaminergic system is the primary site of dysfunction and the opioid system is secondarily aected. 53, 74 Studies also have implicated a possible underactivity of the serotonin and g-aminobutyric acid neurotransmitter systems. 19 Results of SPECT studies have suggested a de®ciency of DA D 2 receptors. 19 However, the involvement of the DA system, like postsynaptic striatal D2 receptors, in RLS and SCA3 is a matter of debate. 48 DA receptors have a diurnal variation paralleling that of the RLS/PLMS syndrome. 53 Exacerbation of RLS in the evening when DA activity is at its lowest level, and exacerbation with iron de®ciency, are further evidence in support of impaired DA transmission in RLS. 17, 57 An increase in the symptoms and the more frequent occurrence of RLS in older people also may re¯ect a decrease of DA activity in old age. 21 Although normal somatosensory and brainstem auditory evoked responses in patients suering from RLS provide no evidence of an aerent sensory disturbance, they support the hypothesis that RLS and PMLS are a re¯ection of the suppression of descending inhibitory in¯uences on pyramidal tract function. Others suggest a disturbance of the inhibitory reticulospinal pathways.
The locus of involuntary motor activity in RLS is likely to be subcortical. 2 A good location for this modulating center would be in the peri-aqueductal gray matter of the midbrain/diencephalon region. It provides the necessary connection to the reticular activating system, it is near the extrapyramidal system, the hypothalamus, and the peduncles for motor transmission and near the sensory relay pathways to account for dysesthesias. 53 Electrophysiologic studies and ®ndings of reduced intracortical inhibition, however, suggest that the underlying abnormality may be at, or rostral to, the pons.
11,67 MRI and PET scanning have drawn attention to the possible role of the upper brainstem and diencephalon. 17 Localization of the RLS induced involuntary movements and their distribution patterns favor a brainstem or spinal cord origin of movements. The ®ndings by Bucher et al 72 indicated that the red nucleus and brainstem are involved in the generation of PLM in patients with RLS. The brainstem activation may re¯ect the disinhibition eects of the reticular formation on spinal pathways. They therefore concluded that reticular structures in the brainstem appear to be the primary generators of RL symptomatology. Based on electrophysiological studies, Trenkwalder et al 55 suggested a brainstem disinhibition phenomenon as the pathophysiological mechanism that activates a spinal generator. Other investigators evoke a diencephalic-spinal DA system. 17 As the face is not involved in RLS, the generator is likely below the level of the facial nucleus in the brainstem. 1 Another hypothesis is that RLS is a spinal or propriospinal rather than a basal ganglia disease. This hypothesis is supported by several observations. DA containing neurons have been demonstrated in the spinal cord. 40, 75, 76 DA receptors have a diurnal variation paralleling that of RLS-PMLS syndrome. Levels of free DA and homovanylic acid (HVA) were found elevated in the spinal¯uid of a patient with RLS-PMLS, indicating a decreased turnover of DA metabolites. 53 DA may help blunt the eect of nociceptive impulses generated by partial deafferentation onto the motor neuron pool. This could occur because: (1) DA itself is de®cient in the spinal cord and is being replaced; or (2) DA has some antinociceptive properties. 40 RLS occurring after myelitis also supports the hypothesis that a lesion of the spinal cord could generate RLS. Hemmer et al 45 speculated that the spinal cord lesion led to an uncovering of a spinal generator triggering the irresistible leg movements. This process may be modulated by abnormal periphery sensory input from, for instance, a peripheral neuropathy. 20 The eect of treatment with DA drugs may be due to a DA in¯uence on the spinal generator rather than on basal ganglion circuits. 61 Recent studies provide evidence of enhanced excitability of the spinal cord mechanisms, facilitated by the loss of supraspinal inhibition, together with the pattern of muscle activation in patients with RLS-PLMS, suggests a propriospinal mechanism. 17 It has been indicated that in patients with PLMS and associated spinal cord lesions the DA system suppresses the activity of the disinhibited lumbosacral generator. 43 Additionally, the occurrence of PLMS in subjects with spinal cord injury, including complete thoracic transection, casts doubt on its central origin. 17 In a study of polio survivors by Bruno, 77 nearly two-thirds of the patients reported abnormal movements in sleep, presenting poliovirus-induced damage to the spinal cord and brain as the possible cause. The manifestation of abnormal movements following a spinal cord injury, multiple sclerosis or spondylosis suggests that the spinal cord can contribute to the genesis of PLMS due to inhibition or release of segments below the lesion. 63 The DA inhibitory role on abnormal motor activity is impaired by the spinal cord lesion and thus might be restored by treatment with DA agents. 58 The decrease in PLM after physical activity can be due to release of b-endorphins suggesting participation of the opioid system. 78 Physical activity by spinal cord injured patients can help minimize sleep complaints, in particular those related to leg movements. 79 The association of RLS with the later stages of pregnancy, with venous insuciency, peripheral embolism, and relief of the symptoms by vasodilators provide support for yet another mechanism in some patients. 11 The vascular theory postulates an impairment in the local circulation, causing ischemia or a build-up of toxic metabolites. Another suggestion considers microcirculatory changes in the small super®cial veins as cause of the restless sensations by stimulation of aerent nerve ®bers. 6 RLS in patients with both saphenous and non-truncal varicose vein disease, responds frequently and rapidly to scleral therapy. 51 The various suggested etiologies reviewed above do not solve the problem of RLS but rather emphasize the need for more clinical and basic research to provide new insights into the pathophysiology of RLS.
Treatment
Treatment of RLS can be broken down into several categories: (a) primary treatment to reduce subjective symptoms; (b) speci®c treatment directed to an underlying cause; (c) ecacy and usefulness of secondary treatment; and (d) ancillary treatments that are non pharmacological modes and may assist therapy.
Primary treatment
Drug therapy for idiopathic RLS is largely symptomatic and must be adapted to the individual patient. 1, 20 In severe cases a combination of medications may be bene®cial. However, the placebo eect in RLS should not be ignored. 80 
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Dopaminergic agents These improve all features of RLS including subjective discomfort, dyskinesias while awake, and sleep quality in PLMS. DA precursors are most often used, either as regular L-dopa/carbidopa (Sinemet) or sustained release (SR) compounds, (Sinemet-CR). A combination therapy of standard and SR-L-Dopa was found more ecient in maintaining sleep and improve symptoms. 81, 82 This has also been found a safe and eective therapy for patients in endstage renal disease with RLS. 18, 34, 83 Various approaches to the treatment of idiopathic and uremic RLS are reviewed by Trenkwalder et al 84 and the practical management of therapy outlined. Janzen et al 34 stated that peak plasma levodopa concentrations are achieved in 15 ± 60 min from the time of administration.
Allen and Earley 85 emphasized the side eects of levo-dopa: the problem with morning end-of-dose rebound that increases leg movements and the markedly augmented RL symptoms occurring in the afternoon and evening prior to taking the next nightly dose. They considered augmentation to be the major adverse eect of treatment and can be even greater for patients with severe RLS. Others also reported on the rebound phenomenon of levo-dopa. 4, 34, 53, 86, 87 Two DA agonists, bromocriptine (Parlodel), and pergolide (Permax), taken in divided doses before bedtime, have been successfully tried. 4, 5, 11, 40, 53, 88 Pergolide is a potent, long-acting ergoline compound with D1 and D2 receptor agonist properties. It has been found superior to L-Dopa in the treatment of RLS and PLMS including its use in uremic patients. 89 ± 92 A side eect of pergolide, however, is a signi®cant symptomatic hypotension; therefore the drug must be increased carefully. 18 A combination of pergolide with domperidone (Motilium) provides a well-tolerated and eective treatment of sensorimotor symptoms and sleep disorder in patients with primary RLS. 93 ± 96 Their mean and maximal daily maintenance doses are comparatively low and the augmentation eects mild. 97, 98 Pramipexole (Mirapex), a full D3-receptor agonist, dramatically reduces PLMS, alleviates leg discomfort at bedtime and during the night and is the most potent therapeutic agent tested for RLS. 71, 99, 100 A preliminary report on the use of ropinirole (Requip), a nonergoline DA agonist with relative greater D3 and D4 anity than pergolide, also appears promising. 101 Benzodiazepines These sedative medications are useful for treatment of both RLS and PLMS. Their major eect is in improving the quality of sleep. Clonazepam (Klonopin) is the more favored medication, but temazepam (Restoril) and triazolam (Halcion) are also being used. 4, 11, 53, 56, 102 Opioids Narcotic medications are clearly useful for treating RLS including codeine, propoxyphene (Darvon), oxycodone HCL, acetaminophen (Percocet) and pentazocine (Talwin). Tolerance and addictive behavior, however, are the main problems. 4, 5, 11 The eective treatment with oxycodone (Percodan) resulting in signi®cant improvement of RLS has been reported. 103 Tramadol (Melanate), a central analgesic seems to be superior in the treatment of RLS. It has fewer side eects and a lower abuse potential than classical opioids. 104 Vahedi et al 105 reported on dramatic relief of severe RLS obtained with epidural morphine after long-standing abuse of various analgesics.
Other medications Recently the use of gabapentin has been recommended as a successful treatment of RLS. g-aminobutyric acid (GABA) is an inhibitory neurotransmitter found mainly in the brain with only traces in peripheral nerves and other tissues. Gabapentin (Neurontin) has been successfully marketed as an anticonvulsive drug. 54, 106, 107 Side eects include dizziness, nausea, and drowsiness. 108 Trazodone (Desyrel) and nefazodone (Serzone) aord complete relief in some mild to moderate cases. 53 In some patients, however, methadone may be the only drug providing relief. 53 Baclofen (Lioresal) has been tried in PLMS, but its eect on RLS is not clear. Clonidine (Catapres), a centrally active a-adrenergic blocker, has been shown to be eective. It has a signi®cant bene®t upon waking symptoms and sleep latency and is particularly useful in treatment of children with RLS. 4 High dose clonidine appears to be valuable in treating RLS when other therapy has failed. 109, 110 Carpamazepine (Tegretol) as well as propranolol hydrochloride (Inderal) are reported to be bene®cial in the treatment of RLS. 11 According to Neustadt, 111 orphenadrine citrate (Nor¯ex) is an extremely eective and safe medication for controlling symptoms of RLS and PLMS. Magnesium treatment may be an acceptable alternative in patients with mild or moderate RLS or PLMS-related insomnia. 112 Other agents mentioned to be useful include red wine, b-blockers, serotonin precursors, tricyclic anti-depressants and acetaminophen. 113 Symptomatic treatment When RLS is due to underlying systemic disorders, treatment of the underlying condition may alleviate the symptoms. De®ciency states may be corrected, such as iron supplementation in iron de®ciency, folate supplements, especially in pregnant women, erythropoietin and transfusions in anemia and dialysis or kidney transplantation for uremia. The rutoside paroven (Venoruton) has a therapeutic eect in RLS patients associated with varicose veins. 6 Other treatments include a number of dierent vitamins such as vitamin C, vitamin E or B-12 and magnesium supplements.
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Adverse responses Contrary to previous belief, smoking reportedly does not in¯uence the symptoms of RLS. 114 Reduction of alcohol intake, however, may be helpful. Medications can precipitate or exacerbate the condition of RLS. Among dietary substances and medications that have been suggested to increase the symptoms are caeine, lithium, neuroleptics and tricyclic antidepressants. 1 Paradoxically, some patients do respond favorably to tricyclics. 4, 18 Recurrence and/or increase in symptoms of RLS was observed after the use of the antidepressants¯uoxetine (Prozac) and sertraline (Zoloft); both being selective serotinin re-uptake inhibitors. 115, 116 Similarly, the occurrence of RLS was observed in association with mianserin, a serotonin-inhibiting antihistamine. 117 Worsening of symptoms has been described with paroxetine (Paxil), a phenylpyperidine derivative. This drug has a low anity for a-adrenergic histamine H-1, serotonin 5-HT2 and dopamine D2 receptors. 80, 118 Ancillary treatment Modulation with activity As a rule physical measures are not very helpful. Non-pharmacologic therapies such as the use of vibration, thermal feedback or transcutaneous electrical nerve stimulation have been suggested. 4, 5, 21 All patients are encouraged to exercise to a reasonable extent. Many RLS patients report that their symptoms appear associated with the degree of physical activity. A moderate degree of exercise tends to suppress symptoms, whereas either sustained activity or bursts of heightened exercise may worsen their symptoms. 4, 18 Coping strategies, learning to live with RLS, and involving the family are essential. With these in mind a support group with newsletters for patients with RLS was established in the United States and Canada and lately in 1995 in Germany.
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Conclusion
RLS is a fairly common condition with a well-de®ned symptom complex and occurs either as idiopathic RLS or in association with many underlying disorders. There is a high incidence of family history and a frequent association with sleep disorders. In idiopathic RLS there are no pathological ®ndings or recognizable intracranial lesions. However, recent PET and SPECT studies revealed some involvement of basal ganglia and upper brainstem.
Although no precise etiology for this condition is known, there is evidence supporting a CNS dysfunction suggestive of involvement of the DA pathways. The disturbance may originate in the midbrain, diencephalon or upper brainstem. In addition there is documentation that RLS occurs with spinal disorders and yet another mechanism for vascular disease may be responsible in some patients.
The treatment of idiopathic RLS is primarily symptomatic and DA agents or agonists and other neurotransmitters are quite eective. The associated underlying diseases of RLS should be treated and de®ciency states corrected.
More basic and clinical research is necessary to obtain a better understanding of the pathophysiology of RLS.
